Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jalm/jfz025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A perspective review on factors that influence mutagenicity in medicinal plants and their health implications.
Toxicol Sci
January 2025
Department of Pharmacology, University of the Free State, Bloemfontein, 9300, South Africa.
Medicinal plants are products from natural sources that have found relevance in medicine for several decades. They are rich in bioactive compounds; thus, they are widely used to treat different ailments globally. Medicinal plants have provided hope for the health care industry as most are used to synthesize modern medicines currently used in the treatment of various diseases.
View Article and Find Full Text PDFLongitudinal FDG-PET Metabolic Change Along the Lewy Body Continuum.
JAMA Neurol
January 2025
Department of Radiology, Mayo Clinic, Rochester, Minnesota.
Importance: Although 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a well-established cross-sectional biomarker of brain metabolism in dementia with Lewy bodies (DLB), the longitudinal change in FDG-PET has not been characterized.
Objective: To investigate longitudinal FDG-PET in prodromal DLB and DLB, including a subsample with autopsy data, and report estimated sample sizes for a hypothetical clinical trial in DLB.
Design, Setting, And Participants: Longitudinal case-control study with mean (SD) follow-up of 3.
Safety and Efficacy of IV Onasemnogene Abeparvovec for Pediatric Patients With Spinal Muscular Atrophy: The Phase 3b SMART Study.
Neurology
January 2025
The Dubowitz Neuromuscular Centre, Developmental Neurosciences Department, University College London, Great Ormond Street Institute of Child Health, United Kingdom.
Background And Objectives: Safety and efficacy of IV onasemnogene abeparvovec has been demonstrated for patients with spinal muscular atrophy (SMA) weighing <8.5 kg. SMART was the first clinical trial to evaluate onasemnogene abeparvovec for participants weighing 8.
View Article and Find Full Text PDFA randomized, crossover trial of one night of oxygen therapy for obstructive sleep apnea in patients with fibrotic interstitial lung disease.
Sleep Breath
January 2025
Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Background And Objective: There is no satisfactory treatment for obstructive sleep apnea (OSA) in patients with interstitial lung disease (ILD) because of poor tolerance of positive airway pressure (PAP) therapy. Supplemental oxygen therapy has been shown to reduce hypoxemia and is well tolerated in patients with ILD. However, little is known about the effect of nocturnal oxygen supplementation (NOS) on OSA in patients with ILD.
View Article and Find Full Text PDFCorrection: Acute myeloid leukemia and myelodysplastic neoplasms: clinical implications of myelodysplasia‑related genes mutations and TP53 aberrations.
Blood Res
January 2025
Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!